Cannabis Abstinence and Neurocognitive Assessment in Adolescence

Cannabis Abstinence and Neurocognitive Assessment in Adolescence

Cannabis Abstinence and Neurocognitive Assessment in Adolescence

Evaluate the development of cognitive functions following attainment of abstinence in a group of adolescents with cannabis dependence or harmful cannabis use. Abstinence is confirmed by toxicological testing.

Inclusion Criteria:

• Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

Exclusion Criteria:

• psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.
• somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.
• Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.